INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31001, 29110, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31002, 29111, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31003, 29212, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31004, 29213, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31005, 29214, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31006, 30447, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31007, 31559, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31008, 32779, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31009, 4005, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31010, 4006, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31011, 4010, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31012, 6386, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31013, 12174, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31014, 17234, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31015, 17235, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31016, 17236, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31017, 18100, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31018, 18106, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31019, 19873, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31020, 19874, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31021, 19875, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31022, 20709, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31023, 20711, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31024, 20712, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31025, 21072, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31026, 29096, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31027, 29097, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31028, 29098, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31029, 29099, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31030, 29103, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31031, 29110, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31032, 29111, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31033, 29212, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31034, 29213, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31035, 29214, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31036, 30447, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31037, 31559, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31038, 32779, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31039, 4005, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31040, 4006, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31041, 4010, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31042, 6386, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31043, 12174, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31044, 17234, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31045, 17235, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31046, 17236, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31047, 18100, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31048, 18106, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31049, 19873, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31050, 19874, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31051, 19875, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31052, 20709, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31053, 20711, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31054, 20712, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31055, 21072, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31056, 29096, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31057, 29097, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31058, 29098, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31059, 29099, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31060, 29103, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31061, 29110, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31062, 29111, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31063, 29212, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31064, 29213, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31065, 29214, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31066, 30447, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31067, 31559, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31068, 32779, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31069, 4005, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31070, 4006, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31071, 4010, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31072, 6386, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31073, 12174, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31074, 17234, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31075, 17235, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31076, 17236, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31077, 18100, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31078, 18106, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31079, 19873, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31080, 19874, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31081, 19875, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31082, 20709, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31083, 20711, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31084, 20712, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31085, 21072, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31086, 29096, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31087, 29097, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31088, 29098, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31089, 29099, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31090, 29103, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31091, 29110, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31092, 29111, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31093, 29212, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31094, 29213, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31095, 29214, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31096, 30447, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31097, 31559, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31098, 32779, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31099, 4005, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31100, 4006, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31101, 4010, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31102, 6386, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31103, 12174, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31104, 17234, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31105, 17235, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31106, 17236, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31107, 18100, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31108, 18106, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31109, 19873, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31110, 19874, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31111, 19875, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31112, 20709, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31113, 20711, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31114, 20712, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31115, 21072, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31116, 29096, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31117, 29097, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31118, 29098, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31119, 29099, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31120, 29103, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31121, 29110, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31122, 29111, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31123, 29212, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31124, 29213, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31125, 29214, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31126, 30447, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31127, 31559, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31128, 32779, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31129, 4005, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31130, 4006, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31131, 4010, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31132, 6386, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31133, 12174, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31134, 17234, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31135, 17235, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31136, 17236, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31137, 18100, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31138, 18106, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31139, 19873, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31140, 19874, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31141, 19875, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31142, 20709, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31143, 20711, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31144, 20712, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31145, 21072, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31146, 29096, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31147, 29097, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31148, 29098, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31149, 29099, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31150, 29103, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31151, 29110, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31152, 29111, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31153, 29212, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31154, 29213, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31155, 29214, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31156, 30447, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31157, 31559, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31158, 32779, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31159, 28911, 'Valganciclovir', 'Neutropenia', 'Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow aplasia, and aplastic anemia have been reported in patients treated with valganciclovir.  The use of this agent should be avoided if the absolute neutrophil count is less than 500 cells/L, the platelet count is less than 25,000//L, or the hemoglobin is less than 8 g/dL.  Complete blood counts with differential and platelet counts should be performed frequently, especially in patients that developed leukopenia after using a nucleoside analog, or in whom neutrophil counts are less than 1000 cells/L at the beginning of treatment.  Therapy with this agent should be administered with caution in patients with bone marrow depression.  Increased monitoring is recommended.', '3', '"Product Information. Valcyte (valganciclovir)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31160, 28911, 'Valganciclovir', 'Kidney Diseases', 'Acute renal failure has been documented in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients.  Adequate hydration, dose reduction and close monitoring of renal function are recommended when using valganciclovir in these patients.  The tablet form of valganciclovir should not be used in adult patients on hemodialysis (CrCl less than 10 mL/min).', '3', '"Product Information. Valcyte (valganciclovir)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31161, 28911, 'Valganciclovir', 'Hepatic Insufficiency', 'Monitoring is recommended when using valganciclovir in patients with hepatic impairment as the safety and efficacy of this agent has not been studied in these patients.', '2', '"Product Information. Valcyte (valganciclovir)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31162, 29091, 'Venetoclax', 'Hepatic Insufficiency', 'In vitro studies demonstrated that venetoclax is predominantly metabolized in the liver by CYP450 3A4/5.  Based on pharmacokinetic analysis with subjects with mild and moderate hepatic impairment, the venetoclax exposures were similar to those with normal hepatic function; therefore, no dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Based on the drug metabolism, an increase in adverse events might result in patients with moderate to severe hepatic impairment.  It is recommended to monitor patients with moderate to severe hepatic impairment carefully for signs of toxicity during the initiation and the weekly dose ramp-up phase.  Caution is advised when using this agent in patients with severe hepatic impairment as it pharmacokinetics has not been studied.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31163, 31915, 'Venetoclax', 'Hepatic Insufficiency', 'In vitro studies demonstrated that venetoclax is predominantly metabolized in the liver by CYP450 3A4/5.  Based on pharmacokinetic analysis with subjects with mild and moderate hepatic impairment, the venetoclax exposures were similar to those with normal hepatic function; therefore, no dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Based on the drug metabolism, an increase in adverse events might result in patients with moderate to severe hepatic impairment.  It is recommended to monitor patients with moderate to severe hepatic impairment carefully for signs of toxicity during the initiation and the weekly dose ramp-up phase.  Caution is advised when using this agent in patients with severe hepatic impairment as it pharmacokinetics has not been studied.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31164, 29091, 'Venetoclax', 'Neutropenia', 'Venetoclax can cause neutropenia.  It is recommended to monitor for fever and signs suggestive of an infection.  Monitor complete blood count during the course of therapy and reduce dose or interrupt treatment for severe neutropenia.  Therapy with this agent should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31165, 31915, 'Venetoclax', 'Neutropenia', 'Venetoclax can cause neutropenia.  It is recommended to monitor for fever and signs suggestive of an infection.  Monitor complete blood count during the course of therapy and reduce dose or interrupt treatment for severe neutropenia.  Therapy with this agent should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31166, 29091, 'Venetoclax', 'Tumor Lysis Syndrome', 'Based on pharmacokinetic analysis with subjects with mild and moderate renal impairment, the venetoclax exposures were similar to those with normal renal function; therefore, no dose adjustment is recommended in these patients.  The pharmacokinetics of venetoclax has not been studied in subjects with severe renal impairment.  Patients with reduced renal function are at increased risk of tumor lysis syndrome (TLS) and these patients may require more intensive monitoring and care to reduce the risk of TLS at the start of treatment.  Patients should be assessed for risk factor that may contribute to an increase risk for TLS and complete blood chemistries should be monitored regularly.  Dose interruption is recommended if needed based on clinical findings.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31167, 31915, 'Venetoclax', 'Tumor Lysis Syndrome', 'Based on pharmacokinetic analysis with subjects with mild and moderate renal impairment, the venetoclax exposures were similar to those with normal renal function; therefore, no dose adjustment is recommended in these patients.  The pharmacokinetics of venetoclax has not been studied in subjects with severe renal impairment.  Patients with reduced renal function are at increased risk of tumor lysis syndrome (TLS) and these patients may require more intensive monitoring and care to reduce the risk of TLS at the start of treatment.  Patients should be assessed for risk factor that may contribute to an increase risk for TLS and complete blood chemistries should be monitored regularly.  Dose interruption is recommended if needed based on clinical findings.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31168, 0, 'Vibrio cholerae CVD 103-HgR strain live antigen (live)', 'IMMUNE SUPPRESSION', 'The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy.  Caution and close monitoring is advised.', '2', '"Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur  (2005):|"Product Information. ActHIB (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur  (2022):|"Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc  (2022):|"Product Information. Trumenba (meningococcal group B vaccine)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Hiberix (haemophilus b conjugate (PRP-T) vaccine)." GlaxoSmithKline  (2022):|"Product Information. Vaxchora (cholera vaccine, live)." PaxVax  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31169, 12071, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31170, 12072, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31171, 12074, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31172, 18077, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31173, 18078, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31174, 21315, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31175, 28959, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31176, 28961, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31177, 28964, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31178, 28966, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31179, 28967, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31180, 29204, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31181, 31576, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31182, 32122, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31183, 32293, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31184, 33827, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31185, 33828, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31186, 12071, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31187, 12072, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31188, 12074, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31189, 18077, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31190, 18078, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31191, 21315, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31192, 28959, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31193, 28961, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31194, 28964, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31195, 28966, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31196, 28967, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31197, 29204, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31198, 31576, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31199, 32122, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31200, 32293, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31201, 33827, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31202, 33828, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31203, 12071, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31204, 12072, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31205, 12074, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31206, 18077, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31207, 18078, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31208, 21315, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31209, 28959, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31210, 28961, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31211, 28964, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31212, 28966, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31213, 28967, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31214, 29204, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31215, 31576, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31216, 32122, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31217, 32293, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31218, 33827, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31219, 33828, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31220, 12071, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31221, 12072, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31222, 12074, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31223, 18077, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31224, 18078, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31225, 21315, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31226, 28959, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31227, 28961, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31228, 28964, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31229, 28966, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31230, 28967, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31231, 29204, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31232, 31576, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31233, 32122, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31234, 32293, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31235, 33827, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31236, 33828, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31237, 12071, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31238, 12072, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31239, 12074, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31240, 18077, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31241, 18078, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31242, 21315, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31243, 28959, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31244, 28961, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31245, 28964, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31246, 28966, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31247, 28967, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31248, 29204, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31249, 31576, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31250, 32122, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31251, 32293, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31252, 33827, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31253, 33828, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31254, 12309, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31255, 12310, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31256, 12311, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31257, 12318, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31258, 12319, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31259, 12309, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31260, 12310, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31261, 12311, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31262, 12318, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31263, 12319, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31264, 12309, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31265, 12310, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31266, 12311, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31267, 12318, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31268, 12319, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31269, 12309, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31270, 12310, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31271, 12311, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31272, 12318, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31273, 12319, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31274, 12309, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31275, 12310, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31276, 12311, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31277, 12318, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31278, 12319, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31279, 12309, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31280, 12310, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31281, 12311, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31282, 12318, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31283, 12319, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31284, 12309, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31285, 12310, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31286, 12311, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31287, 12318, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31288, 12319, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31289, 12309, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31290, 12310, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31291, 12311, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31292, 12318, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31293, 12319, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31294, 17032, 'Vinblastine', 'Infections', 'The use of vinblastine is contraindicated in patients with known infectious diseases.  Vinblastine can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vinblastine.  Close clinical monitoring of hematopoietic function is recommended.  Vinblastine should not be used in patients with neutrophil counts below 1000/mm3.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31295, 29073, 'Vinblastine', 'Infections', 'The use of vinblastine is contraindicated in patients with known infectious diseases.  Vinblastine can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vinblastine.  Close clinical monitoring of hematopoietic function is recommended.  Vinblastine should not be used in patients with neutrophil counts below 1000/mm3.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31296, 17032, 'Vinblastine', 'Bone Marrow Failure Disorders', 'The use of vinblastine is contraindicated in patients with significant granulocytopenia.  Vinblastine induces dose-dependent leukopenia.  Thrombocytopenia and anemia have been reported infrequently during vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31297, 29073, 'Vinblastine', 'Bone Marrow Failure Disorders', 'The use of vinblastine is contraindicated in patients with significant granulocytopenia.  Vinblastine induces dose-dependent leukopenia.  Thrombocytopenia and anemia have been reported infrequently during vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31298, 17032, 'Vinblastine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31299, 29073, 'Vinblastine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31300, 17032, 'Vinblastine', 'Liver Diseases', 'Vinblastine is metabolized by the liver and eliminated primarily via biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity associated with vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients with compromised hepatic function.', '2', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31301, 29073, 'Vinblastine', 'Liver Diseases', 'Vinblastine is metabolized by the liver and eliminated primarily via biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity associated with vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients with compromised hepatic function.', '2', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31302, 10135, 'Vigabatrin', 'Blindness', 'Vigabatrin causes permanent bilateral concentric visual field constriction.  The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.  The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.  Because of the risk of vision loss, and because, when it is effective, vigabatrin provides an observable symptomatic benefit, patient response and continued need for treatment should be periodically assessed.  If the need clearly outweighs the risk, caution should be exercised when using vigabatrin therapy in patients with, or at high risk of, other types of irreversible vision loss.  Vigabatrin should not be used in patients that are being treated for retinopathy or glaucoma.', '3', '"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31303, 10135, 'Vigabatrin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31304, 10135, 'Vigabatrin', 'Neurotoxicity Syndromes', 'Vigabatrin has produced pathological changes in the brains of rats and long-term neurobehavioral abnormalities (convulsions, neuromotor impairment, learning deficits) were also observed.  In humans, abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated for infantile spasms (IS) with vigabatrin.  Studies of the effects of vigabatrin on MRI and changes in visual and somatosensory evoked potentials (EP) in adult epilepsy patients have not been clearly defined.', '2', '"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31305, 10135, 'Vigabatrin', 'Peripheral Nervous System Diseases', 'Vigabatrin causes symptoms of peripheral neuropathy in adults.  There is insufficient evidence to determine if development of these signs and symptoms were related to duration of vigabatrin treatment, cumulative dose, or if the findings of peripheral neuropathy were completely reversible upon discontinuation of vigabatrin.  Therapy with vigabatrin should be administered cautiously in patients with peripheral neuropathy.', '2', '"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31306, 29310, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31307, 29311, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31308, 29312, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31309, 29314, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31310, 29315, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31311, 29316, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31312, 29317, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31313, 29310, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31314, 29311, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31315, 29312, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31316, 29314, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31317, 29315, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31318, 29316, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31319, 29317, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31320, 29310, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31321, 29311, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31322, 29312, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31323, 29314, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31324, 29315, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31325, 29316, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31326, 29317, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31327, 29310, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31328, 29311, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31329, 29312, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31330, 29314, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31331, 29315, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31332, 29316, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31333, 29317, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31334, 29310, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31335, 29311, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31336, 29312, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31337, 29314, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31338, 29315, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31339, 29316, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31340, 29317, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31341, 29310, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31342, 29311, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31343, 29312, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31344, 29314, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31345, 29315, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31346, 29316, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31347, 29317, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31348, 23315, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31349, 23316, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31350, 23317, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31351, 23318, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31352, 29366, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31353, 29367, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31354, 29368, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31355, 29369, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31356, 23315, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31357, 23316, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31358, 23317, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31359, 23318, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31360, 29366, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31361, 29367, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31362, 29368, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31363, 29369, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31364, 23315, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31365, 23316, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31366, 23317, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31367, 23318, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31368, 29366, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31369, 29367, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31370, 29368, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31371, 29369, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31372, 23315, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31373, 23316, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31374, 23317, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31375, 23318, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31376, 29366, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31377, 29367, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31378, 29368, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31379, 29369, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31380, 23315, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31381, 23316, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31382, 23317, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31383, 23318, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31384, 29366, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31385, 29367, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31386, 29368, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31387, 29369, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31388, 23315, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31389, 23316, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31390, 23317, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31391, 23318, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31392, 29366, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31393, 29367, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31394, 29368, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31395, 29369, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31396, 1421, 'Beta carotene', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31397, 1421, 'Beta carotene', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31398, 0, 'Vismodegib', 'Musculoskeletal Diseases', 'Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations have been reported with the use of drugs that inhibit the hedgehog pathway.  It is recommended to obtain serum creatine kinase levels and renal function tests prior to initiating therapy, periodically during treatment, and as clinically indicated.  Care should be taken when prescribing these agents to patients presenting musculoskeletal pain or myalgia.  Temporary dose interruption or discontinuation of therapy may be required based on the severity of musculoskeletal adverse reactions.', '2', '"Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31399, 1172, 'Vitamin A', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31400, 29488, 'Vitamin A', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31401, 1172, 'Vitamin A', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31402, 29488, 'Vitamin A', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31403, 237, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31404, 738, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31405, 750, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31406, 7003, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31407, 9563, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31408, 11867, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31409, 15493, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31410, 15494, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31411, 29596, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31412, 29597, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31413, 29598, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31414, 29599, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31415, 237, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31416, 738, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31417, 750, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31418, 7003, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31419, 9563, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31420, 11867, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31421, 15493, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31422, 15494, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31423, 29596, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31424, 29597, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31425, 29598, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31426, 29599, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31427, 237, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31428, 738, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31429, 750, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31430, 7003, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31431, 9563, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31432, 11867, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31433, 15493, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31434, 15494, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31435, 29596, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31436, 29597, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31437, 29598, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31438, 29599, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31439, 237, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31440, 738, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31441, 750, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31442, 7003, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31443, 9563, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31444, 11867, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31445, 15493, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31446, 15494, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31447, 29596, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31448, 29597, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31449, 29598, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31450, 29599, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31451, 237, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31452, 738, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31453, 750, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31454, 7003, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31455, 9563, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31456, 11867, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31457, 15493, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31458, 15494, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31459, 29596, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31460, 29597, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31461, 29598, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31462, 29599, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31463, 1699, 'Von Willebrand Factor Human', 'Thromboembolism', 'Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):|"Product Information. Wilate (antihemophilic factor-von Willebrand factor)." Octapharma USA  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31464, 15463, 'Von Willebrand Factor Human', 'Thromboembolism', 'Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):|"Product Information. Wilate (antihemophilic factor-von Willebrand factor)." Octapharma USA  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31465, 7018, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31466, 12493, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31467, 18674, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31468, 28247, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31469, 28248, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31470, 29463, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31471, 29506, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31472, 29508, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31473, 29511, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31474, 7018, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31475, 12493, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31476, 18674, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31477, 28247, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31478, 28248, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31479, 29463, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31480, 29506, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31481, 29508, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31482, 29511, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31483, 0, 'Vorapaxar', 'Hemorrhage', 'Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer.  In other patients, consider the underlying risk of bleeding before initiating therapy.  General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications.  The use of warfarin and other anticoagulants should be avoided.  Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.', '3', '"Product Information. Zontivity (vorapaxar)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31484, 0, 'Vorapaxar', 'Ischemic Stroke', 'Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding.  The risk of intracranial bleeding is higher in these patients.', '3', '"Product Information. Zontivity (vorapaxar)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31485, 0, 'Vorapaxar', 'Liver Diseases', 'No dose adjustment is required in patients with renal dysfunction or mild to moderate hepatic impairment.  Vorapaxar is not recommended in patients with severe hepatic impairment due to bleeding risk.', '3', '"Product Information. Zontivity (vorapaxar)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31486, 0, 'Vorinostat', 'Thromboembolism', 'The use of vorinostat may cause pulmonary embolism and deep vein thrombosis.  It is recommended to monitor for signs and symptoms of these events, particularly in patients with a prior history of thromboembolic events.', '3', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31487, 0, 'Vorinostat', 'Diabetes Mellitus', 'The use of vorinostat may cause hyperglycemia.  It is recommended to monitor serum glucose every 2 weeks during the first 2 months of therapy and monthly thereafter.  Care should be exercised when using this agent in diabetic patients.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31488, 0, 'Vorinostat', 'Gastrointestinal Diseases', 'The use of vorinostat may cause gastrointestinal disturbances.  It is recommended to adequately control any preexisting nausea, vomiting, and diarrhea prior to beginning treatment with vorinostat.  Fluid and electrolytes should be replaced to prevent dehydration and the use of antiemetic and antidiarrheal medications may be appropriate.  Correct hypokalemia and hypomagnesemia prior to administration of vorinostat.  Monitor potassium and magnesium more frequently in symptomatic patients.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31489, 0, 'Vorinostat', 'Liver Failure', 'Compared to patients with normal liver function, AUC increases of 50 to 66% were observed in patients with hepatic impairment.  It is recommended to reduce the starting dose of vorinostat to 300 mg orally once daily with food in patients with mild to moderate hepatic impairment (bilirubin 1 to 3  ULN or AST greater than ULN).  There is insufficient evidence to recommend a starting dose for patients with severe hepatic impairment (bilirubin greater than 3  ULN).  Precautions should be instituted when using this agent in patients with liver dysfunction.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31490, 0, 'Vorinostat', 'Bone Marrow Failure Disorders', 'The use of vorinostat can cause dose-related thrombocytopenia and anemia.  It is recommended to monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter.  Adjust dosage or discontinue treatment as clinically appropriate.  Care should be exercised when using this agent in patients with bone marrow suppression.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31491, 12260, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31492, 14824, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31493, 16702, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31494, 16703, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31495, 18521, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31496, 19469, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31497, 29218, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31498, 29591, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31499, 29592, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31500, 29593, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31501, 29594, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31502, 12260, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31503, 14824, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31504, 16702, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31505, 16703, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31506, 18521, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31507, 19469, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31508, 29218, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31509, 29591, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31510, 29592, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31511, 29593, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31512, 29594, 'Voriconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31513, 12260, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31514, 14824, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31515, 16702, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31516, 16703, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31517, 18521, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31518, 19469, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31519, 29218, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31520, 29591, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31521, 29592, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31522, 29593, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31523, 29594, 'Voriconazole', 'Kidney Diseases', 'The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (CrCl less than 50 mL/min).  The mean systemic exposure (AUC) and Cmax of SBECD were increased 4-fold and almost 50%, respectively, in moderately impaired patients compared to controls with normal renal function.  The manufacturer recommends that oral voriconazole be used in patients with moderate to severe renal dysfunction, unless after assessing benefit/risk to the patient, use of IV voriconazole is justified; serum creatinine levels should be monitored closely in these patients, and if increases occur, switching to oral voriconazole should be considered.  No dosage adjustment is necessary when using oral voriconazole.  Monitoring of renal function (including laboratory evaluation of serum creatinine) is recommended.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31524, 12260, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31525, 14824, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31526, 16702, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31527, 16703, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31528, 18521, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31529, 19469, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31530, 29218, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31531, 29591, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31532, 29592, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31533, 29593, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31534, 29594, 'Voriconazole', 'Pancreatitis', 'Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.', '2', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31535, 0, 'Yellow Fever Vaccine', 'Infections', 'Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure.  However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient''s symptoms and their etiology.  Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial.  In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished.  On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered.  In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops.  In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.', '3', '"Product Information. Typhim VI (typhoid vaccine, inactivated)." Apothecon Inc  (2022):|"Product Information. Varivax (varicella virus vaccine)." Merck & Co., Inc  (2022):|"Product Information. Pneumovax 23 (pneumococcal 23-polyvalent vaccine)." Merck & Co., Inc  (2022):|"Product Information. Mumpsvax (mumps virus vaccine)." Merck & Co., Inc  (2022):|"Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):|"Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):|"Product Information. Orimune (poliovirus vaccine, live, trivalent)." Lederle Laboratories  (2022):|"Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):|"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham|"Product Information. Menomune A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught Laboratories Inc|"Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc  (2001):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|"Product Information. Cholera Vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories|"Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham|"Product Information. Engerix-B (hepatitis B adult vaccine)." Apothecon Inc  (2022):|"Product Information. Zostavax (zoster vaccine live)." Merck & Co., Inc  (2006):|"Product Information. Gardasil (human papillomavirus vaccine)." Merck & Co., Inc  (2006):|"Product Information. Gardasil 9 (human papillomavirus vaccine)." Merck & Co., Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31536, 0, 'Yellow Fever Vaccine', 'Immune Deficiency Disease', 'In general, the use of yellow fever vaccine is contraindicated in patients with primary or acquired immunodeficiency.  Since yellow fever vaccine contains live attenuated virus, the absence of immune competence may potentiate the replication of vaccine virus, increase adverse host reactions, and compromise serum antibody response.  In patients with severe immunosuppression or known HIV infection, the use of yellow fever vaccine may pose a theoretical risk of encephalitis.  Asymptomatic HIV-infected patients may be vaccinated if potential exposure to yellow fever virus is deemed unavoidable.  However, they should be monitored for adverse effects, and it may be necessary to have neutralizing antibody titers obtained before departure to gauge the adequacy of the serum antibody response.  Finally, the vaccine should not be administered to anyone with a family history of congenital or hereditary immunodeficiency until the individual''s immune status can be assessed and is determined to be adequate.', '3', '"Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31537, 5162, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31538, 5748, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31539, 6934, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31540, 9139, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31541, 10093, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31542, 12360, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31543, 12862, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31544, 21381, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31545, 22920, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31546, 23655, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31547, 23947, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31548, 27269, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31549, 29930, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31550, 29948, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31551, 29953, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31552, 29954, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31553, 31302, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31554, 31649, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31555, 31650, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31556, 31651, 'Zinc acetate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31557, 5162, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31558, 5748, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31559, 6934, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31560, 9139, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31561, 10093, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31562, 12360, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31563, 12862, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31564, 21381, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31565, 22920, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31566, 23655, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31567, 23947, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31568, 27269, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31569, 29930, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31570, 29948, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31571, 29953, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31572, 29954, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31573, 31302, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31574, 31649, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31575, 31650, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31576, 31651, 'Zinc acetate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31577, 0, 'Zileuton', 'Liver Diseases', 'The use of zileuton is contraindicated in patients with active liver disease or transaminase elevations >= 3 times the upper limit of normal (ULN).  Zileuton is primarily metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, zileuton may cause elevation of serum transaminases, usually during the first two months of therapy but in a few cases, after treatment has been discontinued.  During clinical trials, the overall rate of ALT (SGPT) elevation >= 3 times the ULN in patients treated with zileuton was 3.2%.  The manufacturer recommends periodic monitoring of hepatic transaminases.  Serum ALT should be evaluated prior to starting treatment, once a month for the first three months, every 2 to 3 months for the remainder of the first year, and periodically thereafter for patients receiving long-term zileuton therapy.  If clinical signs and/or symptoms of liver dysfunction occur or transaminase levels increase to 5 times the ULN, treatment should be stopped, and transaminase levels followed until normal.  Because of the potential hepatotoxicity, zileuton should be used with caution in patients with a history of liver disease or alcoholism.', '3', '"Product Information. Zyflo (zileuton)." Abbott Pharmaceutical', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31578, 10558, 'Zaleplon', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31579, 26927, 'Zaleplon', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31580, 27083, 'Zaleplon', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31581, 27084, 'Zaleplon', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31582, 29828, 'Zaleplon', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31583, 10558, 'Zaleplon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31584, 26927, 'Zaleplon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31585, 27083, 'Zaleplon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31586, 27084, 'Zaleplon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31587, 29828, 'Zaleplon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31588, 10558, 'Zaleplon', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31589, 26927, 'Zaleplon', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31590, 27083, 'Zaleplon', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31591, 27084, 'Zaleplon', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31592, 29828, 'Zaleplon', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31593, 10558, 'Zaleplon', 'Liver Diseases', 'Zaleplon is primarily metabolized by the liver.  The oral clearance of zaleplon has been shown to decrease by 70% and 87% in patients with compensated and decompensated cirrhosis, respectively, compared to healthy patients.  Associated plasma drug concentrations were markedly increased by several-fold.  Therapy with zaleplon is not recommended in patients with severely impaired hepatic function.  The dosage should be reduced to 5 mg in patients with mild to moderate hepatic impairment.', '3', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31594, 26927, 'Zaleplon', 'Liver Diseases', 'Zaleplon is primarily metabolized by the liver.  The oral clearance of zaleplon has been shown to decrease by 70% and 87% in patients with compensated and decompensated cirrhosis, respectively, compared to healthy patients.  Associated plasma drug concentrations were markedly increased by several-fold.  Therapy with zaleplon is not recommended in patients with severely impaired hepatic function.  The dosage should be reduced to 5 mg in patients with mild to moderate hepatic impairment.', '3', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31595, 27083, 'Zaleplon', 'Liver Diseases', 'Zaleplon is primarily metabolized by the liver.  The oral clearance of zaleplon has been shown to decrease by 70% and 87% in patients with compensated and decompensated cirrhosis, respectively, compared to healthy patients.  Associated plasma drug concentrations were markedly increased by several-fold.  Therapy with zaleplon is not recommended in patients with severely impaired hepatic function.  The dosage should be reduced to 5 mg in patients with mild to moderate hepatic impairment.', '3', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31596, 27084, 'Zaleplon', 'Liver Diseases', 'Zaleplon is primarily metabolized by the liver.  The oral clearance of zaleplon has been shown to decrease by 70% and 87% in patients with compensated and decompensated cirrhosis, respectively, compared to healthy patients.  Associated plasma drug concentrations were markedly increased by several-fold.  Therapy with zaleplon is not recommended in patients with severely impaired hepatic function.  The dosage should be reduced to 5 mg in patients with mild to moderate hepatic impairment.', '3', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31597, 29828, 'Zaleplon', 'Liver Diseases', 'Zaleplon is primarily metabolized by the liver.  The oral clearance of zaleplon has been shown to decrease by 70% and 87% in patients with compensated and decompensated cirrhosis, respectively, compared to healthy patients.  Associated plasma drug concentrations were markedly increased by several-fold.  Therapy with zaleplon is not recommended in patients with severely impaired hepatic function.  The dosage should be reduced to 5 mg in patients with mild to moderate hepatic impairment.', '3', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31598, 10558, 'Zaleplon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31599, 26927, 'Zaleplon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31600, 27083, 'Zaleplon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31601, 27084, 'Zaleplon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31602, 29828, 'Zaleplon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31603, 10558, 'Zaleplon', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31604, 26927, 'Zaleplon', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31605, 27083, 'Zaleplon', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31606, 27084, 'Zaleplon', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31607, 29828, 'Zaleplon', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31608, 10558, 'Zaleplon', 'Kidney Diseases', 'Zaleplon is excreted in the urine almost exclusively as metabolites and their glucuronides.  The pharmacokinetics of zaleplon are not altered in patients with renal insufficiency.  According to the manufacturer, dosage adjustments are not necessary in patients with mild to moderate renal impairment.  However, caution may be appropriate if the drug is used in patients with severe renal impairment, since data establishing its safety and efficacy are lacking in such patients.', '2', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31609, 26927, 'Zaleplon', 'Kidney Diseases', 'Zaleplon is excreted in the urine almost exclusively as metabolites and their glucuronides.  The pharmacokinetics of zaleplon are not altered in patients with renal insufficiency.  According to the manufacturer, dosage adjustments are not necessary in patients with mild to moderate renal impairment.  However, caution may be appropriate if the drug is used in patients with severe renal impairment, since data establishing its safety and efficacy are lacking in such patients.', '2', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31610, 27083, 'Zaleplon', 'Kidney Diseases', 'Zaleplon is excreted in the urine almost exclusively as metabolites and their glucuronides.  The pharmacokinetics of zaleplon are not altered in patients with renal insufficiency.  According to the manufacturer, dosage adjustments are not necessary in patients with mild to moderate renal impairment.  However, caution may be appropriate if the drug is used in patients with severe renal impairment, since data establishing its safety and efficacy are lacking in such patients.', '2', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31611, 27084, 'Zaleplon', 'Kidney Diseases', 'Zaleplon is excreted in the urine almost exclusively as metabolites and their glucuronides.  The pharmacokinetics of zaleplon are not altered in patients with renal insufficiency.  According to the manufacturer, dosage adjustments are not necessary in patients with mild to moderate renal impairment.  However, caution may be appropriate if the drug is used in patients with severe renal impairment, since data establishing its safety and efficacy are lacking in such patients.', '2', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31612, 29828, 'Zaleplon', 'Kidney Diseases', 'Zaleplon is excreted in the urine almost exclusively as metabolites and their glucuronides.  The pharmacokinetics of zaleplon are not altered in patients with renal insufficiency.  According to the manufacturer, dosage adjustments are not necessary in patients with mild to moderate renal impairment.  However, caution may be appropriate if the drug is used in patients with severe renal impairment, since data establishing its safety and efficacy are lacking in such patients.', '2', '"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|Dooley M, Plosker GL "Zaleplon - A review of its use in the treatment of insomnia." Drugs 60 (2000):  413-45', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31613, 7733, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31614, 7735, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31615, 7743, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31616, 7744, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31617, 12582, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31618, 16859, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31619, 20164, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31620, 20165, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31621, 20166, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31622, 20167, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31623, 22288, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31624, 22300, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31625, 33148, 'Warfarin', 'Hemorrhage', 'In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, severe hepatic impairment, and myeloproliferative disorders such as leukemia or polycythemia vera.  Additionally, oral anticoagulants are usually contraindicated in the presence of any active ulceration of the gastrointestinal, respiratory, or genitourinary tracts; cerebrovascular hemorrhage; aneurysms (cerebral, dissecting aortic); pericarditis and pericardial effusions; bacterial endocarditis; and eclampsia, preeclampsia, or threatened abortion.  These patients may be at increased risk for uncontrollable hemorrhage or bleeding complications during therapy with oral anticoagulants.  Other potential contraindications include diverticulitis, vasculitis, malnutrition, and vitamin C or vitamin K deficiency.  The decision to administer anticoagulants must be based upon clinical judgment in which the risks are weighed against the benefits in each patient.', '3', 'Dajani YF "Hematuria in patients on anticoagulants." N Engl J Med 297 (1977):  222|Levine MN, Hirsh J "Hemorrhagic complications of anticoagulant therapy." Semin Thromb Hemost 12 (1986):  39-57|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Lee KS, Marwick T "Hemopericardium and cardiac tamponade associated with warfarin therapy." Cleve Clin J Med 60 (1993):  336-8|Landefeld CS, Rosenblatt MW, Goldman L "Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions." Am J Med 87 (1989):  153-9|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Brigden ML "When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat." Postgrad Med 98 (1995):  153|White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S "Management and prognosis of life-threatening bleeding during warfarin therapy." Arch Intern Med 156 (1996):  1197-201|Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, Dangelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devote G, Berrettini M, "Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)." Lancet 348 (1996):  423-8|Morgan RJ, Bristol JB "Unusual findings in a patient taking warfarin - Retroperitoneal haematoma." Postgrad Med J 75 (1999):  299-300|Jimenez J "Abdominal pain in a patient using warfarin - Intramural haematoma of the small bowel in the setting of the warfarin anticoagulation." Postgrad Med J 75 (1999):  747-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31626, 7733, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31627, 7735, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31628, 7743, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31629, 7744, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31630, 12582, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31631, 16859, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31632, 20164, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31633, 20165, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31634, 20166, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31635, 20167, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31636, 22288, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31637, 22300, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31638, 33148, 'Warfarin', 'Diabetes Mellitus', 'Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '3', '"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31639, 7733, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31640, 7735, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31641, 7743, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31642, 7744, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31643, 12582, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31644, 16859, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31645, 20164, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31646, 20165, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31647, 20166, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31648, 20167, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31649, 22288, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31650, 22300, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31651, 33148, 'Warfarin', 'Hypertension', 'In general, the use of oral anticoagulants is contraindicated in patients with malignant or severe, uncontrolled hypertension.  These patients may be at increased risk for cerebral hemorrhage.  Therapy with oral anticoagulants should be administered cautiously in patients with moderate hypertension.', '3', 'Hylek EM, Singer DE "Risk factors for intracranial hemorrhage in outpatients taking warfarin." Ann Intern Med 120 (1994):  897-902|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31652, 7733, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31653, 7735, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31654, 7743, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31655, 7744, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31656, 12582, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31657, 16859, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31658, 20164, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31659, 20165, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31660, 20166, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31661, 20167, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31662, 22288, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31663, 22300, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31664, 33148, 'Warfarin', 'Liver Diseases', 'Oral anticoagulants (coumarin and indandione derivatives) are primarily metabolized by the liver.  Patients with hepatic impairment may have a heightened response to these agents due to decreased clearance of the drugs as well as defective hemostasis associated with impaired synthesis of clotting factors by the liver.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate liver disease.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools', '3', 'Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Williams RL, Schary WL, Blaschke TF, et al. "Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin." Clin Pharmacol Ther 20 (1976):  90-7|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31665, 7733, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31666, 7735, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31667, 7743, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31668, 7744, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31669, 12582, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31670, 16859, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31671, 20164, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31672, 20165, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31673, 20166, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31674, 20167, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31675, 22288, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31676, 22300, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31677, 33148, 'Warfarin', 'Protein C Deficiency', 'Tissue necrosis is a rare complication that develops during the initiation of oral anticoagulant therapy due to thrombotic occlusion of venules in the dermis and subcutaneous tissues.  Hereditary, familial, or clinical deficiencies of protein C or its cofactor, protein S, may be associated with a hypercoagulable state and an increased risk of the complication.  Therapy with oral anticoagulants should be administered cautiously in patients with known or suspected deficiency in protein C-mediated anticoagulant response.  Concomitant administration with heparin for the first 5 to 7 days of oral anticoagulant therapy may minimize the risk.  If tissue necrosis develops, oral anticoagulant therapy should be discontinued promptly and vitamin K or frozen plasma administered at once.  Heparin should then be considered for anticoagulation.', '3', 'Cole MS, Minifee PK, Wolma FJ "Coumarin necrosis: a review of the literature." Surgery 103 (1988):  271-7|Humphries JE, Gardner JH, Connelly JE "Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy." Am J Hematol 37 (1991):  197-200|Horn JR, Danziger LH, Davis RJ "Warfarin-induced skin necrosis: report of four cases." Am J Hosp Pharm 38 (1981):  1763-8|Kandrotas RJ, Deterding J "Genital necrosis secondary to warfarin therapy." Pharmacotherapy 8 (1988):  351-4|Locht H, Lindstrom FD "Severe skin necrosis following warfarin therapy in a patient with protein C deficiency." J Intern Med 233 (1993):  287-9|Colman RW, Rao AK, Rubin RN "Warfarin skin necrosis in a 33-year-old woman." Am J Hematol 43 (1993):  300-3|LaPrade RF, Fowler BL, Ryan TG "Skin necrosis with minidose warfarin used for prophylaxis against thromboembolic disease after hip surgery." Orthopedics 16 (1993):  703-4|Eby CS "Warfarin-induced skin necrosis." Hematol Oncol Clin North Am 7 (1993):  1291-300|Griffin JP "Anticoagulants and skin necrosis." Adverse Drug React Toxicol Rev 13 (1994):  157-67|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Stewart AJ, Penman ID, Cook MK, Ludlam CA "Warfarin-induced skin necrosis." Postgrad Med J 75 (1999):  233-5|Zimbelman J, Lefkowitz J, Schaeffer C, Hays T, MancoJohnson M, Manhalter C, Nuss R "Unusual complications of warfarin therapy: Skin necrosis and priapism." J Pediat 137 (2000):  266-8|Cheng A, Scheinfeld NS, McDowell B, Dokras AA "Warfarin skin necrosis in a postpartum woman with protein S deficiency." Obstet Gynecol 90(4 Pt 2) (1997):  671-2|Mehta RL, Scott G, Sloand JA, Francis CW "Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis." Am J Med 88 (1990):  252-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31678, 7733, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31679, 7735, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31680, 7743, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31681, 7744, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31682, 12582, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31683, 16859, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31684, 20164, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31685, 20165, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31686, 20166, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31687, 20167, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31688, 22288, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31689, 22300, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31690, 33148, 'Warfarin', 'Coumarin Resistance', 'Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.', '2', 'Ganeval D, Fischer AM, Barre J, et al. "Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors." Clin Nephrol 25 (1986):  75-80|Rice AJ, McIntosh TJ, Fouts JR, et al. "Decrease sensitivity to warfarin in patients with myxedema." Am J Med Sci 262 (1971):  211-5|Walters MB "The relationship between thyroid function and anticoagulant therapy." Am J Cardiol 11 (1963):  112-4|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Stephens MA, Self TH, Lancaster D, Nash T "Hypothyroidism: effect on warfarin anticoagulation." South Med J 82 (1989):  1585-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31691, 7733, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31692, 7735, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31693, 7743, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31694, 7744, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31695, 12582, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31696, 16859, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31697, 20164, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31698, 20165, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31699, 20166, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31700, 20167, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31701, 22288, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31702, 22300, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31703, 33148, 'Warfarin', 'Coumarin Sensitivity', 'Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or steatorrhea may exhibit greater than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and dosage adjustment of anticoagulant may be required based on changes in the patient''s condition.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Vagenakis AG, Cote R, Miller ME, et al. "Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis." Johns Hopkins Med J 131 (1972):  69-73|Owens JC, Neely WB, Owen WR "Effect of sodium dextrothyroxine in patients receiving anticoagulants." N Engl J Med 266 (1962):  76-9|Self T, Weisburst M, Wooten E, Straughn A, Oliver J "Warfarin-induced hypoprothrombinemia: potentiation by hyperthyroidism." JAMA 231 (1975):  1165-6|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Black JA "Diarrhoea, vitamin k, and warfarin." Lancet 344 (1994):  1373|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455|Smith JK, Aljazairi A, Fuller SH "INR elevation associated with diarrhea in a patient receiving warfarin." Ann Pharmacother 33 (1999):  301-4|Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD "Problems of anticoagulation with warfarin in hyperthyroidism." Q J Med 58 (1986):  43-51|Self TH, Straughn AB, Weisburst MR "Effect of hyperthryroidism on hypoprothrombinemic response to warfarin." Am J Hosp Pharm 33 (1976):  387-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31704, 7733, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31705, 7735, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31706, 7743, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31707, 7744, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31708, 12582, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31709, 16859, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31710, 20164, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31711, 20165, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31712, 20166, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31713, 20167, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31714, 22288, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31715, 22300, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31716, 33148, 'Warfarin', 'Kidney Diseases', 'There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However, patients with renal impairment may demonstrate platelet defects and may be at increased risk for bleeding.  Therapy with oral anticoagulants should be administered cautiously in patients with severe or moderate renal dysfunction.  The INR should be monitored closely, and patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', '2', 'Bachmann K, Shapiro R, Mackiewicz J "Influence of renal dysfunction on warfarin plasma protein binding." J Clin Pharmacol 16 (1976):  468-72|Yacobi A, Udall JA, Levy G "Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect." Clin Pharmacol Ther 19 (1976):  552-8|Bachmann K, Shapiro R, Mackiewicz J "Warfarin elimination and responsiveness in patients with renal dysfunction." J Clin Pharmacol 17 (1977):  292-9|Shetty HG, Fennerty AG, Routledge PA "Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy." Clin Pharmacokinet 16 (1989):  238-53|Landfeld CS, Goldman L "Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy." Am J Med 87 (1989):  144-52|Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|"Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals  (2001):|Demirkan K, Stephens MA, Newman KP, Self TH "Response to warfarin and other oral anticoagulants: effects of disease states." South Med J 93 (2000):  448-54; quiz 455', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31717, 5162, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31718, 5748, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31719, 6934, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31720, 9139, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31721, 10093, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31722, 12360, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31723, 12862, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31724, 21381, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31725, 22920, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31726, 23655, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31727, 23947, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31728, 27269, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31729, 29930, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31730, 29948, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31731, 29953, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31732, 29954, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31733, 31302, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31734, 31649, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31735, 31650, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31736, 31651, 'Zinc sulfate', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31737, 5162, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31738, 5748, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31739, 6934, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31740, 9139, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31741, 10093, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31742, 12360, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31743, 12862, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31744, 21381, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31745, 22920, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31746, 23655, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31747, 23947, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31748, 27269, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31749, 29930, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31750, 29948, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31751, 29953, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31752, 29954, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31753, 31302, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31754, 31649, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31755, 31650, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31756, 31651, 'Zinc sulfate', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '"Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA  (2001):|"Product Information. Chroma-Pak (chromic chloride hexahydrate)." Apothecon Inc  (2022):|"Product Information. Sele-Pak (selenium)." Fujisawa|"Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group  (2001):|"Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical  (2001):|"Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31757, 453, 'Zafirlukast', 'Liver Diseases', 'The use of zafirlukast may be associated with elevations of one or more liver enzymes as well as life-threatening hepatic failure.  Cases of liver injury without other attributable cause have been reported from postmarketing surveillance of patients treated with the recommended dosage of zafirlukast (40 mg/day).  Although most cases have been reversible following drug discontinuation, fulminant hepatitis and progression to hepatic failure, liver transplantation, and death have rarely been reported.  In patients with hepatic cirrhosis, serum zafirlukast concentrations may be 50% to 60% higher than in normal patients.  Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis.  Periodic serum transaminase testing is recommended to enable early detection of drug-induced hepatic injury.  Patients should be advised to contact their physician immediately if they experience signs or symptoms of liver dysfunction (e.g., right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver).  Zafirlukast should be discontinued, and liver function tests performed immediately if hepatic injury is suspected.  The drug should not be resumed if hepatic injury is confirmed.  Patients in whom zafirlukast was withdrawn because of hepatic injury where no other attributable cause is identified should not be re-exposed to zafirlukast.', '3', '"Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals  (2001):|Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995):  463-70,473-4|Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997):  1012-21|Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ "Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast." Ann Intern Med 133 (2000):  964-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31758, 13309, 'Zafirlukast', 'Liver Diseases', 'The use of zafirlukast may be associated with elevations of one or more liver enzymes as well as life-threatening hepatic failure.  Cases of liver injury without other attributable cause have been reported from postmarketing surveillance of patients treated with the recommended dosage of zafirlukast (40 mg/day).  Although most cases have been reversible following drug discontinuation, fulminant hepatitis and progression to hepatic failure, liver transplantation, and death have rarely been reported.  In patients with hepatic cirrhosis, serum zafirlukast concentrations may be 50% to 60% higher than in normal patients.  Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis.  Periodic serum transaminase testing is recommended to enable early detection of drug-induced hepatic injury.  Patients should be advised to contact their physician immediately if they experience signs or symptoms of liver dysfunction (e.g., right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver).  Zafirlukast should be discontinued, and liver function tests performed immediately if hepatic injury is suspected.  The drug should not be resumed if hepatic injury is confirmed.  Patients in whom zafirlukast was withdrawn because of hepatic injury where no other attributable cause is identified should not be re-exposed to zafirlukast.', '3', '"Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals  (2001):|Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995):  463-70,473-4|Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997):  1012-21|Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ "Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast." Ann Intern Med 133 (2000):  964-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31759, 22926, 'Zafirlukast', 'Liver Diseases', 'The use of zafirlukast may be associated with elevations of one or more liver enzymes as well as life-threatening hepatic failure.  Cases of liver injury without other attributable cause have been reported from postmarketing surveillance of patients treated with the recommended dosage of zafirlukast (40 mg/day).  Although most cases have been reversible following drug discontinuation, fulminant hepatitis and progression to hepatic failure, liver transplantation, and death have rarely been reported.  In patients with hepatic cirrhosis, serum zafirlukast concentrations may be 50% to 60% higher than in normal patients.  Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis.  Periodic serum transaminase testing is recommended to enable early detection of drug-induced hepatic injury.  Patients should be advised to contact their physician immediately if they experience signs or symptoms of liver dysfunction (e.g., right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver).  Zafirlukast should be discontinued, and liver function tests performed immediately if hepatic injury is suspected.  The drug should not be resumed if hepatic injury is confirmed.  Patients in whom zafirlukast was withdrawn because of hepatic injury where no other attributable cause is identified should not be re-exposed to zafirlukast.', '3', '"Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals  (2001):|Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995):  463-70,473-4|Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997):  1012-21|Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ "Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast." Ann Intern Med 133 (2000):  964-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31760, 29114, 'Zafirlukast', 'Liver Diseases', 'The use of zafirlukast may be associated with elevations of one or more liver enzymes as well as life-threatening hepatic failure.  Cases of liver injury without other attributable cause have been reported from postmarketing surveillance of patients treated with the recommended dosage of zafirlukast (40 mg/day).  Although most cases have been reversible following drug discontinuation, fulminant hepatitis and progression to hepatic failure, liver transplantation, and death have rarely been reported.  In patients with hepatic cirrhosis, serum zafirlukast concentrations may be 50% to 60% higher than in normal patients.  Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis.  Periodic serum transaminase testing is recommended to enable early detection of drug-induced hepatic injury.  Patients should be advised to contact their physician immediately if they experience signs or symptoms of liver dysfunction (e.g., right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver).  Zafirlukast should be discontinued, and liver function tests performed immediately if hepatic injury is suspected.  The drug should not be resumed if hepatic injury is confirmed.  Patients in whom zafirlukast was withdrawn because of hepatic injury where no other attributable cause is identified should not be re-exposed to zafirlukast.', '3', '"Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals  (2001):|Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995):  463-70,473-4|Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997):  1012-21|Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ "Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast." Ann Intern Med 133 (2000):  964-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31761, 0, 'Voxelotor', 'Hepatic Insufficiency', 'Dose reduction for voxelotor is recommended for patients with severe hepatic impairment.  The daily recommended dose for these patients is 1,000 mg.  No dosage adjustment is required for patients with mild or moderate hepatic impairment.', '2', '"Product Information. Oxbryta (voxelotor)." Global Blood Therapeutics, Inc.  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31762, 0, 'Voxelotor', 'Hypersensitivity', 'Serious hypersensitivity reactions have occurred in patients treated with voxelotor.  If hypersensitivity reactions occur, discontinue treatment and administer appropriate medical therapy.  Do not reinitiate voxelotor in patients who experience hypersensitivity reactions with previous use.', '2', '"Product Information. Oxbryta (voxelotor)." Global Blood Therapeutics, Inc.  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31763, 29913, 'Zidovudine', 'Bone Marrow Failure Disorders', 'Zidovudine (AZT) may cause bone marrow toxicity, most commonly manifested as granulocytopenia and anemia, particularly in patients with advanced, symptomatic HIV disease.  Thrombocytopenia not related to HIV may also occasionally occur.  Zidovudine should be given with extreme caution to patients with preexisting bone marrow depression (indicated by a granulocyte count below 1000 cells/mm3 or hemoglobin less than 9.5 g/dL) or blood dyscrasias.  Routine blood counts are recommended, and generally should occur more frequently in patients with advanced HIV disease.  Dosage reductions may be necessary.', '3', 'Goldsmith JC, Irvine W "Reversible agranulocytosis related to azidothymidine therapy." Am J Hematol 30 (1989):  263-4|Baum MK, Javier JJ, Mantero-Atienza E, et al. "Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males." J Acquir Immune Defic Syndr 4 (1991):  1218-26|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31764, 29913, 'Zidovudine', 'Muscular Diseases', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and telbivudine may commonly cause myopathy, including rare cases of rhabdomyolysis.  The myopathy may be dose-related and is characterized by persistent, unexplained muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values.  Therapy with these NRTIs should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  NRTI therapy should be interrupted if drug-related myopathy is suspected, and discontinued if myopathy is diagnosed.', '3', '"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31765, 29913, 'Zidovudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31766, 29913, 'Zidovudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31767, 0, 'Zanamivir', 'Asthma', 'Serious respiratory adverse events, including bronchospasm and/or decline in lung function, have been reported during clinical trials and postmarketing use of zanamivir.  The manufacturer does not generally recommend its use in patients with underlying airways disease such as asthma or chronic obstructive pulmonary disease.  However, if it is prescribed, these patients should have a fast-acting inhaled bronchodilator readily available whenever zanamivir is administered.  The drug should be stopped and the physician notified in case of worsening respiratory symptoms.  Patients scheduled to use an inhaled bronchodilator at the same time as the zanamivir dose should use their bronchodilator before administering zanamivir.', '3', '"Product Information. Relenza (zanamivir)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31768, 1447, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31769, 1458, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31770, 1474, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31771, 1475, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31772, 1477, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31773, 15107, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31774, 15108, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31775, 15109, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31776, 15133, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31777, 15150, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31778, 15151, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31779, 16914, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31780, 16915, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31781, 19635, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31782, 26465, 'Betamethasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31783, 1447, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31784, 1458, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31785, 1474, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31786, 1475, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31787, 1477, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31788, 15107, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31789, 15108, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31790, 15109, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31791, 15133, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31792, 15150, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31793, 15151, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31794, 16914, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31795, 16915, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31796, 19635, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31797, 26465, 'Betamethasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31798, 1447, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31799, 1458, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31800, 1474, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31801, 1475, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31802, 1477, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31803, 15107, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31804, 15108, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31805, 15109, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31806, 15133, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31807, 15150, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31808, 15151, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31809, 16914, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31810, 16915, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31811, 19635, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31812, 26465, 'Betamethasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31813, 1447, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31814, 1458, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31815, 1474, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31816, 1475, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31817, 1477, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31818, 15107, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31819, 15108, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31820, 15109, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31821, 15133, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31822, 15150, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31823, 15151, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31824, 16914, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31825, 16915, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31826, 19635, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31827, 26465, 'Betamethasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31828, 1447, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31829, 1458, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31830, 1474, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31831, 1475, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31832, 1477, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31833, 15107, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31834, 15108, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31835, 15109, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31836, 15133, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31837, 15150, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31838, 15151, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31839, 16914, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31840, 16915, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31841, 19635, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31842, 26465, 'Betamethasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31843, 54, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31844, 5163, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31845, 12926, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31846, 13347, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31847, 22624, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31848, 24154, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31849, 24341, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31850, 27684, 'Zoledronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31851, 54, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31852, 5163, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31853, 12926, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31854, 13347, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31855, 22624, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31856, 24154, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31857, 24341, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31858, 27684, 'Zoledronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|Watts NB "Treatment of osteoporosis with bisphosphonates." Rheum Dis Clin North Am 20 (1994):  717-34|Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998):  779-89|Schussheim DH, Jacobs TP, Silverberg SJ "Hypocalcemia associated with alendronate." Ann Intern Med 130 (1999):  329|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31859, 54, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31860, 5163, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31861, 12926, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31862, 13347, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31863, 22624, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31864, 24154, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31865, 24341, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31866, 27684, 'Zoledronic acid', 'Kidney Diseases', 'Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment.  No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.  Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each zoledronic acid injection dose.  Acute renal failure (ARF) has been observed in patients after a single administration.  If history or physical signs suggest dehydration, zoledronic acid injection therapy should be withheld until normovolemic status has been achieved.  Zoledronic acid injection should be used with caution in patients with chronic renal impairment.  Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney.', '3', '"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31867, 54, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31868, 5163, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31869, 12926, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31870, 13347, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31871, 22624, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31872, 24154, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31873, 24341, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31874, 27684, 'Zoledronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '"Product Information. Fosamax (alendronate)." Merck & Co., Inc  (2001):|"Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):|"Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):|"Product Information. Reclast (zoledronic acid)." Quality Care Products/Lake Erie Medical  (2011):|"Product Information. Binosto (alendronate)." Mission Pharmacal Company  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31875, 5183, 'Zanubrutinib', 'Arrhythmias, Cardiac', 'Atrial fibrillation and atrial flutter have occurred in patients treated with zanubrutinib monotherapy.  Care should be exercised when using this agent in patients with cardiac risk factors, hypertension, and acute infections as they may be at increased risk of cardiac arrhythmias.  It is recommended to monitor for signs and symptoms of atrial fibrillation and atrial flutter and manage as appropriate.', '2', '"Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31876, 5183, 'Zanubrutinib', 'Hemorrhage', 'Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with zanubrutinib.  These complications have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy.  Special care should be taken when this agent is co-administered with antiplatelet or anticoagulant medications as it may further increase the risk of hemorrhage.  It is recommended to monitor for signs and symptoms of bleeding and to discontinue zanubrutinib if intracranial hemorrhage of any grade occurs.  Consider the benefit-risk of withholding treatment for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.', '2', '"Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31877, 5183, 'Zanubrutinib', 'Pancytopenia', 'Cytopenias, including neutropenia, thrombocytopenia, and anemia were reported in patients treated with zanubrutinib.  Care should be taken when using this agent in patients with hematological abnormalities.  It is recommended to monitor complete blood counts during treatment and treat using growth factor or transfusions, as needed.', '2', '"Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31878, 5183, 'Zanubrutinib', 'Hepatic Insufficiency', 'The safety of zanubrutinib has not been evaluated in patients with severe hepatic impairment.  Dosage modification of zanubrutinib is recommended in patients with severe hepatic impairment.  The recommended dose for patients with severe hepatic impairment is 80 mg orally twice daily.  No dosage modification is recommended in patients with mild to moderate hepatic impairment.  Monitor for adverse reactions in patients with hepatic impairment.', '2', '"Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31879, 5183, 'Zanubrutinib', 'Infections', 'Fatal and serious infections including bacterial, viral, or fungal and opportunistic infections have occurred in patients with hematological malignancies treated with zanubrutinib.  Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia, and other infections according to standard of care in patients who are at increased risk for infections.  Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.', '2', '"Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31880, 5183, 'Zanubrutinib', 'Kidney Diseases', 'The effect of severe renal impairment (CrCl < 30 mL/min) and dialysis on zanubrutinib pharmacokinetics is unknown.  It is recommended to monitor for adverse reactions these patient populations.  No dosage modification is recommended in patients with mild to moderate renal impairment (CrCl > 30 mL/min, estimated by Cockroft-Gault).', '2', '"Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31881, 525, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31882, 2939, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31883, 2941, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31884, 8951, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31885, 10668, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31886, 23688, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31887, 27257, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31888, 32479, 'Zolmitriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31889, 525, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31890, 2939, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31891, 2941, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31892, 8951, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31893, 10668, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31894, 23688, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31895, 27257, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31896, 32479, 'Zolmitriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31897, 525, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31898, 2939, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31899, 2941, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31900, 8951, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31901, 10668, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31902, 23688, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31903, 27257, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31904, 32479, 'Zolmitriptan', 'Liver Diseases', 'Zolmitriptan is primarily metabolized by the liver.  Following oral administration in patients with severe hepatic impairment, plasma concentrations of zolmitriptan were significantly increased (up to several-fold) compared to healthy controls.  Some patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose, presumably due to drug accumulation.  Therapy with zolmitriptan should be administered cautiously in patients with impaired hepatic function.  Lower dosages, no more than 2.5 mg, as well as blood pressure monitoring should be considered in patients with moderate or severe hepatic impairment.', '3', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31905, 525, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31906, 2939, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31907, 2941, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31908, 8951, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31909, 10668, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31910, 23688, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31911, 27257, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31912, 32479, 'Zolmitriptan', 'Kidney Diseases', 'Zolmitriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment, the clearance of zolmitriptan was not significantly altered in patients with moderate impairment (CrCl = 26 to 50 mL/min) but was reduced by 25% in patients with severe impairment (CrCl = 5 to 25 mL/min) compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31913, 1447, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31914, 1458, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31915, 1474, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31916, 1475, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31917, 1477, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31918, 15107, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31919, 15108, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31920, 15109, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31921, 15133, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31922, 15150, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31923, 15151, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31924, 16914, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31925, 16915, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31926, 19635, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31927, 26465, 'Betamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31928, 1447, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31929, 1458, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31930, 1474, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31931, 1475, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31932, 1477, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31933, 15107, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31934, 15108, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31935, 15109, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31936, 15133, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31937, 15150, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31938, 15151, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31939, 16914, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31940, 16915, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31941, 19635, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31942, 26465, 'Betamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31943, 1447, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31944, 1458, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31945, 1474, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31946, 1475, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31947, 1477, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31948, 15107, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31949, 15108, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31950, 15109, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31951, 15133, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31952, 15150, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31953, 15151, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31954, 16914, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31955, 16915, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31956, 19635, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31957, 26465, 'Betamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31958, 1447, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31959, 1458, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31960, 1474, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31961, 1475, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31962, 1477, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31963, 15107, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31964, 15108, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31965, 15109, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31966, 15133, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31967, 15150, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31968, 15151, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31969, 16914, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31970, 16915, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31971, 19635, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31972, 26465, 'Betamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31973, 1447, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31974, 1458, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31975, 1474, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31976, 1475, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31977, 1477, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31978, 15107, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31979, 15108, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31980, 15109, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31981, 15133, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31982, 15150, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31983, 15151, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31984, 16914, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31985, 16915, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31986, 19635, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31987, 26465, 'Betamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31988, 1447, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31989, 1458, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31990, 1474, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31991, 1475, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31992, 1477, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31993, 15107, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31994, 15108, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31995, 15109, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31996, 15133, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31997, 15150, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31998, 15151, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31999, 16914, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32000, 16915, 'Betamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);